Consorci Sanitari Del Garraf News Today : Breaking News, Live Updates & Top Stories | Vimarsana

No benefit was seen in non-hospitalized patients with mild-to-moderate Covid-19 Adding azithromycin to standard-of-care treatment did not significantly decrease hospitalizations or death among patients with mild-to-moderate Covid-19 enrolled in the ATOMIC2 study. The study failed to show a benefit for the antibiotic at a dosage of 500 milligrams daily for 14 days among patients in ....

United Kingdom , Comunidad Autonoma De Cataluna , Psalynn Boyles , Alejandro Rodriquez Molinero , Astra Zeneca , Timothy Hinks , National Institute For Health Research , Oxford Biomedical Research Centre , University Of Oxford , Lancet Respiratory , Consorci Sanitari Del Garraf , Contributing Writer , National Institute , Health Research Oxford Biomedical Centre , Wellcome Trust , Beit Fellowship , Health Research , Peer Voice ,